Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SangStat Med. (SANG) - 10 of 10 analysts say Strong Buy -- Ignore unavailable to you. Want to Upgrade?

To: pwrmstr who wrote (76)	2/9/1998 8:19:00 PM
From: John S. Sturges	Respond to of 184

I believe Zenapax will be seen as a Cyclosporin replacement, the study was designed to test this. Early indications given as part of the FDA panel meeting which resulted in FDA approval Dec. '97 were exceptional. Further data to be given Feb. 18th., full study to be reported in May '97. Because Zenapax is specific for T-Cells and not a general immune system suppressant, it lacks many of the side-effects of Cyclosporin. T-Cell activity has been shown to be the primary cause of organ transplant rejection. The only failure of Zenapax was in a Retinitis study related to HIV infection, in this instance Zenapax given intravenously did not enter the eye fluid and was not effective. The data will prove itself or it won't Feb 18th. Best regards, John